Global Attention Deficit Hyperactivity Disorder (ADHD) Market: Industry Analysis & Outlook (2018-2022)
Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that impacts an individual ability to focus, self-control and perform other skills important in daily life. ADHD is caused due to biochemical, connectivity and the structural difference in the mind. Symptoms of the Attention Deficit Hyperactivity Disorder (ADHD) mostly advances over a period of time and varies according to the type of causing factor and according to the age group of the person. The common symptoms in patient population are trouble at work, low self-esteem and substance abuse or addiction, low-stress tolerance level, mood swings and many more. Further, on the basis of symptoms, ADHD is classified into three key categories including the predominantly inattentive, predominantly hyperactive-impulsive and combined type. ADHD is diagnosed using a comprehensive evaluation of the patient mental and behavior condition. Various treatment options are pharmacological treatment, educational interventions & other behavioral therapies and EEG biofeedback therapies, physicians could reduce the disorder symptoms and its effects on the individual health.
The U.S. emerged as a major region for the ADHD market due to increased healthcare expenditure incurred on the treatment & diagnosis of the ADHD patients and growth in the number of hospitals & clinics offering EEG biofeedback & dual therapy.
The global attention deficit hyperactivity disorder (ADHD) market is expected to grow with increasing pharmaceutical R&D spending, growing healthcare expenditure, accelerating economic growth, unmet treatment needs and mounting occurrence of ADHD. Key trends and developments of this market includes progressing drugs under pipeline, high demand for dual therapy and rising preference for EEG biofeedback therapy. However, there are some factors which can hinder growth of the market including Medical complications of existing drug therapies, high domination of generic pharmaceutical market and strict government protocols.
The report “Global Attention Deficit Hyperactivity Disorder (ADHD) Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with the global market. The report profiles the key players of the market including Shire Plc, Johnson and Johnson, Eli Lilly and Company and Novartis International AG.
The U.S. emerged as a major region for the ADHD market due to increased healthcare expenditure incurred on the treatment & diagnosis of the ADHD patients and growth in the number of hospitals & clinics offering EEG biofeedback & dual therapy.
The global attention deficit hyperactivity disorder (ADHD) market is expected to grow with increasing pharmaceutical R&D spending, growing healthcare expenditure, accelerating economic growth, unmet treatment needs and mounting occurrence of ADHD. Key trends and developments of this market includes progressing drugs under pipeline, high demand for dual therapy and rising preference for EEG biofeedback therapy. However, there are some factors which can hinder growth of the market including Medical complications of existing drug therapies, high domination of generic pharmaceutical market and strict government protocols.
The report “Global Attention Deficit Hyperactivity Disorder (ADHD) Market: Industry Analysis & Outlook (2018-2022)” by Koncept Analytics provides an extensive research and detailed analysis of the present market along with future outlook. The report discusses the major growth drivers, key tends & developments and challenges of the market, covering the U.S., Europe along with the global market. The report profiles the key players of the market including Shire Plc, Johnson and Johnson, Eli Lilly and Company and Novartis International AG.
1. ADHD OVERVIEW
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.4 Classification
1.5 Diagnosis
1.6 Treatment
2. GLOBAL ADHD MARKET
2.1 Global ADHD Market Value Forecast
2.2 Global ADHD Market Value by Region
2.3 Global ADHD Patient Population Forecast
3. REGIONAL ADHD MARKET
3.1 The U.S.
3.1.1 The U.S. ADHD Market Value
3.1.2 The U.S. ADHD Market Value Forecast
3.1.3 The U.S. ADHD Market Revenue by Drugs
3.1.4 The U.S. Vyvanse Drug Revenue Forecast
3.1.5 The U.S. Adderall Generics (IR & XR) Drug Revenue Forecast
3.1.6 The U.S. Adderall XR Drug Revenue Forecast
3.1.7 The U.S. ADHD Drugs Revenue by Categories
3.1.8 The U.S. ADHD Adult Patient Population Forecast
3.1.9 The U.S. ADHD Total Prescriptions
3.1.10 The U.S. ADHD Total Prescriptions Forecast
3.1.11 The U.S. ADHD Total Prescriptions by Drugs
3.1.12 The U.S. Adderall Generics (IR & XR) Total Prescriptions Forecast
3.1.13 The U.S. Vyvanse Total Prescriptions Forecast
3.1.14 The U.S. Concerta Total Prescriptions Forecast
3.2 Europe
3.2.1 Europe ADHD Market Value Forecast
3.2.2 Europe ADHD Patient Population Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Increasing Pharmaceutical R&D Spending
4.1.2 Growing Healthcare Expenditure
4.1.3 Accelerating Economic Growth
4.1.4 Unmet Treatment Needs
4.1.5 Mounting Occurrence of ADHD
4.2 Key Trends and Developments
4.2.1 Progressing Drugs under Pipeline
4.2.2 High Demand for Dual Therapy
4.2.3 Rising Preference for EEG Biofeedback Therapy
4.3 Challenges
4.3.1 Medical Complications of Existing Drug Therapies
4.3.2 High Domination of Generic Pharmaceutical Market
4.3.3 Strict Government Protocols
5. COMPETITIVE LANDSCAPE
5.1 Global ADHD Market
5.1.1 Key Players – Revenues Comparison
5.1.2 Key Players - Market Cap Comparison
5.1.3 Key Players – ADHD Prescription Cost Comparison
6. COMPANY PROFILES
6.1 Shire Plc
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Johnson and Johnson
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novartis International AG
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
List of Figures
Categories of ADHD by Symptoms
Global ADHD Market Value Forecast (2017-2022)
Global ADHD Market Value by Region (2017)
Global ADHD Patient Population Forecast (2017-2022)
The U.S. ADHD Market Value (2013-2017)
The U.S. ADHD Market Value Forecast (2018-2022)
The U.S. ADHD Market Revenue by Drugs* (2017)
The U.S. Vyvanse Drug Revenue Forecast (2017-2022)
The U.S. Adderall Generics (IR & XR) Drug Revenue Forecast (2017-2022)
The U.S. Adderall XR Drug Revenue Forecast (2017-2022)
The U.S. ADHD Drugs Revenue by Categories (2017)
The U.S. ADHD Adult Patient Population Forecast (2017-2022)
The U.S. ADHD Total Prescriptions (2013-2017)
The U.S. ADHD Total Prescriptions Forecast (2018-2022)
The U.S. ADHD Total Prescriptions by Drugs (2017)
The U.S. Adderall Generics (IR & XR) Total Prescriptions Forecast (2017-2022)
The U.S. Vyvanse Total Prescriptions Forecast (2017-2022)
The U.S. Concerta Total Prescriptions Forecast (2017-2022)
Europe ADHD Market Value Forecast (2017-2022)
Europe ADHD Patient Population Forecast (2017-2022)
Global Pharmaceutical R&D Spending (2013-2017)
Global Healthcare Expenditure (2013-2017)
Global GDP Per Capita (2013-2017)
Key Players - Market Cap Comparison (2018*)
Shire Net Revenues by Therapeutic Areas (2017)
Shire Net Revenues and Net Income (2013-2017)
Shire R&D Expenditures (2015-2017)
Shire A&P Expenditures (2015-2017)
J&J Net Sales by Business Segments (2017)
J&J Net Sales and Net Earnings (2013-2017)
J&J R&D Expenditures (2015-2017)
Eli Lilly Revenues by Business Segments (2017)
Eli Lilly Revenues and Net Income (Loss) (2013-2017)
Eli Lilly A&P Expenditures (2015-2017)
Novartis Net Sales by Business Segments (2017)
Novartis Net Sales and Net Income (2013-2017)
Novartis R&D Expenditures (2015-2017)
1.1 Introduction
1.2 Causes
1.3 Symptoms
1.4 Classification
1.5 Diagnosis
1.6 Treatment
2. GLOBAL ADHD MARKET
2.1 Global ADHD Market Value Forecast
2.2 Global ADHD Market Value by Region
2.3 Global ADHD Patient Population Forecast
3. REGIONAL ADHD MARKET
3.1 The U.S.
3.1.1 The U.S. ADHD Market Value
3.1.2 The U.S. ADHD Market Value Forecast
3.1.3 The U.S. ADHD Market Revenue by Drugs
3.1.4 The U.S. Vyvanse Drug Revenue Forecast
3.1.5 The U.S. Adderall Generics (IR & XR) Drug Revenue Forecast
3.1.6 The U.S. Adderall XR Drug Revenue Forecast
3.1.7 The U.S. ADHD Drugs Revenue by Categories
3.1.8 The U.S. ADHD Adult Patient Population Forecast
3.1.9 The U.S. ADHD Total Prescriptions
3.1.10 The U.S. ADHD Total Prescriptions Forecast
3.1.11 The U.S. ADHD Total Prescriptions by Drugs
3.1.12 The U.S. Adderall Generics (IR & XR) Total Prescriptions Forecast
3.1.13 The U.S. Vyvanse Total Prescriptions Forecast
3.1.14 The U.S. Concerta Total Prescriptions Forecast
3.2 Europe
3.2.1 Europe ADHD Market Value Forecast
3.2.2 Europe ADHD Patient Population Forecast
4. MARKET DYNAMICS
4.1 Growth Drivers
4.1.1 Increasing Pharmaceutical R&D Spending
4.1.2 Growing Healthcare Expenditure
4.1.3 Accelerating Economic Growth
4.1.4 Unmet Treatment Needs
4.1.5 Mounting Occurrence of ADHD
4.2 Key Trends and Developments
4.2.1 Progressing Drugs under Pipeline
4.2.2 High Demand for Dual Therapy
4.2.3 Rising Preference for EEG Biofeedback Therapy
4.3 Challenges
4.3.1 Medical Complications of Existing Drug Therapies
4.3.2 High Domination of Generic Pharmaceutical Market
4.3.3 Strict Government Protocols
5. COMPETITIVE LANDSCAPE
5.1 Global ADHD Market
5.1.1 Key Players – Revenues Comparison
5.1.2 Key Players - Market Cap Comparison
5.1.3 Key Players – ADHD Prescription Cost Comparison
6. COMPANY PROFILES
6.1 Shire Plc
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Johnson and Johnson
6.2.1 Business Overview
6.2.2 Financial Overview
6.2.3 Business Strategies
6.3 Eli Lilly and Company
6.3.1 Business Overview
6.3.2 Financial Overview
6.3.3 Business Strategies
6.4 Novartis International AG
6.4.1 Business Overview
6.4.2 Financial Overview
6.4.3 Business Strategies
List of Figures
Categories of ADHD by Symptoms
Global ADHD Market Value Forecast (2017-2022)
Global ADHD Market Value by Region (2017)
Global ADHD Patient Population Forecast (2017-2022)
The U.S. ADHD Market Value (2013-2017)
The U.S. ADHD Market Value Forecast (2018-2022)
The U.S. ADHD Market Revenue by Drugs* (2017)
The U.S. Vyvanse Drug Revenue Forecast (2017-2022)
The U.S. Adderall Generics (IR & XR) Drug Revenue Forecast (2017-2022)
The U.S. Adderall XR Drug Revenue Forecast (2017-2022)
The U.S. ADHD Drugs Revenue by Categories (2017)
The U.S. ADHD Adult Patient Population Forecast (2017-2022)
The U.S. ADHD Total Prescriptions (2013-2017)
The U.S. ADHD Total Prescriptions Forecast (2018-2022)
The U.S. ADHD Total Prescriptions by Drugs (2017)
The U.S. Adderall Generics (IR & XR) Total Prescriptions Forecast (2017-2022)
The U.S. Vyvanse Total Prescriptions Forecast (2017-2022)
The U.S. Concerta Total Prescriptions Forecast (2017-2022)
Europe ADHD Market Value Forecast (2017-2022)
Europe ADHD Patient Population Forecast (2017-2022)
Global Pharmaceutical R&D Spending (2013-2017)
Global Healthcare Expenditure (2013-2017)
Global GDP Per Capita (2013-2017)
Key Players - Market Cap Comparison (2018*)
Shire Net Revenues by Therapeutic Areas (2017)
Shire Net Revenues and Net Income (2013-2017)
Shire R&D Expenditures (2015-2017)
Shire A&P Expenditures (2015-2017)
J&J Net Sales by Business Segments (2017)
J&J Net Sales and Net Earnings (2013-2017)
J&J R&D Expenditures (2015-2017)
Eli Lilly Revenues by Business Segments (2017)
Eli Lilly Revenues and Net Income (Loss) (2013-2017)
Eli Lilly A&P Expenditures (2015-2017)
Novartis Net Sales by Business Segments (2017)
Novartis Net Sales and Net Income (2013-2017)
Novartis R&D Expenditures (2015-2017)
LIST OF TABLES
Drugs under Development for ADHD (2018)
Medical Complications of Existing Drug Therapies
Generic vs. Patented Drugs Price Comparison (2018)
Key Players – Revenues Comparison (2017)
Key Players – ADHD Prescription Cost Comparison (2018)
J&J Significant Agreements (2018/2017)
Drugs under Development for ADHD (2018)
Medical Complications of Existing Drug Therapies
Generic vs. Patented Drugs Price Comparison (2018)
Key Players – Revenues Comparison (2017)
Key Players – ADHD Prescription Cost Comparison (2018)
J&J Significant Agreements (2018/2017)
